Aurobindo Pharma Ltd.

BSE: AUROPHARMA524804ISIN INE406A01037

Healthcare
Pharmaceuticals
BSE 200

Share price

₹1,701.10+2.10 (+0.12%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,739.95
52W low: ₹1,106.25
Off 52W high: -2.23%
1M return: +1.86%
3M return: +5.44%
6M return: +14.68%
1Y return: +47.79%
20D avg volume: 46,739
50 DMA: ₹1,665.33
200 DMA: ₹1,464.58

Key ratios Consolidated

Market cap: ₹97,878 Cr
Current price: ₹1,701.10
52W high / low: ₹1,739.95 / ₹1,106.25
Face value: ₹1.00
P/E: 26.38
P/B: 2.61
EPS (TTM): ₹64.49
Book value / share: ₹652.39
ROE: —
ROCE: 13.60%
Operating margin: —
Net margin: —
Debt / equity: 0.20
Net debt: ₹484.80 Cr
Interest cover: 14.31
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 147.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	9,150	8,853	8,646	8,286	7,868	8,382	7,979	7,796	7,567	7,580	7,352	7,219
	264.23	117.04	187.64	120.59	105.30	134.81	157.29	136.00	220.93	135.62	162.52	186.98
	9,415	8,970	8,834	8,406	7,973	8,517	8,136	7,932	7,788	7,716	7,514	7,406
	7,858	7,677	7,430	7,132	6,769	7,150	6,938	6,725	6,463	6,351	6,249	6,332
	2,894	2,505	2,755	2,510	2,535	2,800	2,729	2,742	2,467	2,635	2,676	2,709
	931.78	931.48	892.65	846.05	807.80	636.18	823.89	747.03	680.01	785.95	775.75	631.07
	1,480	1,374	1,310	1,277	1,229	1,163	1,132	1,109	1,072	1,026	989.68	954.97
	101.66	98.21	92.77	95.24	97.75	115.02	118.48	112.70	111.04	89.43	75.55	68.18
	486.82	478.57	464.73	429.19	405.70	444.43	418.53	382.28	404.18	354.33	423.27	417.50
	2,162	2,298	2,081	1,991	1,797	2,000	1,904	1,910	1,803	1,806	1,610	1,624
	1,557	1,293	1,403	1,274	1,205	1,367	1,198	1,207	1,325	1,365	1,265	1,075
	-40.18	0.00	-65.33	0.00	0.00	0.00	0.00	0.00	0.00	-122.11	0.00	0.00
	1,517	1,293	1,338	1,274	1,205	1,367	1,198	1,207	1,325	1,243	1,265	1,075
	483.06	369.77	428.72	427.79	382.60	432.26	354.28	390.51	405.67	322.55	322.45	323.70
	1,032	920.84	909.80	848.13	824.20	902.83	845.57	816.95	918.22	907.35	939.97	751.94
	17.86	15.86	15.67	14.61	14.20	15.56	14.56	14.00	15.69	15.51	16.04	12.83
Key metrics
	2,105	1,870	1,896	1,799	1,708	1,927	1,735	1,702	1,840	1,686	1,764	1,560
	23.00%	21.10%	21.90%	21.70%	21.70%	23.00%	21.70%	21.80%	24.30%	22.20%	24.00%	21.60%
	11.30%	10.40%	10.50%	10.20%	10.50%	10.80%	10.60%	10.50%	12.10%	12.00%	12.80%	10.40%
	—	3.40%	—	3.70%	—	4.20%	—	—	—	—	—	—
	16.30%	5.60%	8.40%	6.30%	4.00%	10.60%	8.50%	8.00%	—	—	—	—
	25.20%	2.00%	7.60%	3.80%	-10.20%	-0.50%	-10.00%	8.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	34,935	33,653	31,724	29,002	24,855	23,455	24,775	23,098	19,564	16,500
	689.50	492.09	621.85	557.38	290.59	320.35	380.84	86.20	115.66	101.98
	35,625	34,145	32,346	29,559	25,146	23,776	25,155	23,185	19,679	16,602
	30,097	28,970	27,248	24,970	22,522	20,244	20,571	19,400	16,502	13,364
	10,664	10,305	10,737	10,776	9,653	7,372	8,317	7,725	7,445	5,629
	3,602	3,478	2,887	2,773	2,050	1,952	2,315	2,112	1,943	1,606
	5,442	5,190	4,476	3,923	3,522	3,451	3,535	3,219	2,585	2,131
	387.88	383.97	457.24	289.71	140.48	48.64	74.49	159.77	162.66	77.71
	1,859	1,778	1,649	1,522	1,245	1,127	1,055	966.71	667.95	—
	8,532	8,129	7,639	6,633	6,282	5,478	6,004	5,280	4,314	3,828
	5,528	5,176	5,098	4,589	2,624	3,532	4,584	3,784	3,177	3,238
	-105.51	-65.33	0.00	-191.86	0.00	-127.97	2,815	-26.13	-88.06	3.14
	5,422	5,110	5,098	4,397	2,624	3,404	7,399	3,758	3,089	3,241
	1,709	1,609	1,583	1,211	684.85	725.63	2,010	913.51	726.85	818.28
	3,711	3,503	3,484	3,169	1,928	2,647	5,334	2,830	2,364	2,423
	64.00	60.34	59.81	54.16	32.90	45.19	91.04	48.32	40.36	—
Key metrics
	7,669	7,272	7,205	6,209	4,009	4,579	8,529	4,885	3,919	3,319
	21.95%	21.60%	22.70%	21.40%	16.10%	19.50%	34.40%	21.10%	20.00%	20.10%
	10.62%	10.40%	11.00%	10.90%	7.80%	11.30%	21.50%	12.20%	12.10%	14.70%
	—	13.60%	15.80%	—	—	—	—	—	—	—
	9.09%	6.10%	9.40%	16.70%	6.00%	-5.30%	7.30%	18.10%	18.60%	—
	9.48%	0.60%	9.90%	64.40%	-27.20%	-50.40%	88.50%	19.70%	-2.40%	—
	—	2,841	1,957	—	—	—	—	—	—	—
	—	1.58	1.13	—	—	—	—	—	—	—
	—	0.20	0.24	—	—	—	—	—	—	—
	—	484.80	2,373	—	—	—	—	—	—	—
	—	147.2	139.2	—	—	—	—	—	—	—
Balance sheet
	—	58,502	49,785	—	—	—	—	—	—	—
	—	32,709	27,162	—	—	—	—	—	—	—
	—	7,191	5,569	—	—	—	—	—	—	—
	—	7,094	5,746	—	—	—	—	—	—	—
	—	12,053	10,544	—	—	—	—	—	—	—
	—	2,803	2,357	—	—	—	—	—	—	—
	—	14,330	12,189	—	—	—	—	—	—	—
	—	5,567	4,189	—	—	—	—	—	—	—
	—	18,039	14,682	—	—	—	—	—	—	—
	—	7,676	7,942	—	—	—	—	—	—	—
	—	6,873	6,380	—	—	—	—	—	—	—
	—	802.75	1,562	—	—	—	—	—	—	—
	—	37,883	32,647	—	—	—	—	—	—	—
Cash flow
	—	5,526	3,925	—	—	—	—	—	—	—
	—	-3,458	-1,875	—	—	—	—	—	—	—
	—	-1,269	119.78	—	—	—	—	—	—	—
	—	2,686	1,968	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,800	2,787	2,747	2,790	2,848	2,732	2,917	2,825	2,460	2,894	2,692	2,669
	241.89	214.09	130.15	159.52	83.77	113.98	54.26	122.66	65.32	122.97	331.13	67.08
	3,041	3,001	2,877	2,949	2,932	2,846	2,971	2,947	2,525	3,017	3,023	2,736
	2,033	2,124	2,078	2,194	2,182	2,290	2,338	2,224	2,079	2,237	2,336	2,226
	1,289	1,252	1,403	1,244	1,340	1,361	1,507	1,425	1,318	1,402	1,466	1,518
	0.00	16.52	20.15	22.15	14.38	16.31	19.06	16.16	13.60	17.01	155.09	15.77
	295.91	292.71	291.10	294.37	282.97	273.11	265.15	265.48	259.33	248.91	248.08	247.51
	47.07	47.27	48.43	57.45	60.00	61.09	66.19	51.63	51.13	53.07	61.25	36.69
	68.99	71.93	71.92	71.49	70.02	93.88	68.28	68.16	66.88	64.81	64.35	65.79
	380.51	401.45	379.99	403.07	375.99	424.84	445.95	428.58	405.61	464.86	401.00	369.09
	1,008	876.31	799.28	755.28	750.09	555.52	632.94	723.75	446.24	779.88	687.22	509.78
	0.00	0.00	-17.38	0.00	0.00	0.00	—	—	—	—	—	—
	1,008	876.31	781.90	755.28	750.09	555.52	632.94	723.75	446.24	779.88	687.22	509.78
	270.86	184.08	199.83	173.91	190.96	147.35	160.89	186.22	117.20	201.21	63.44	130.13
	737.22	692.23	582.07	581.37	559.13	408.17	472.05	537.53	329.04	578.67	623.78	415.74
	12.75	11.92	10.02	10.01	9.63	7.03	8.13	9.21	5.62	9.88	10.65	6.48
Key metrics
	1,124	995.51	902.25	884.22	880.11	710.49	767.41	843.54	564.25	897.76	812.82	612.26
	40.20%	35.70%	32.80%	31.70%	30.90%	26.00%	26.30%	29.90%	22.90%	31.00%	30.20%	22.90%
	26.30%	24.80%	21.20%	20.80%	19.60%	14.90%	16.20%	19.00%	13.40%	20.00%	23.20%	15.60%
	—	4.00%	—	3.70%	—	2.90%	—	—	—	—	—	—
	-1.70%	2.00%	-5.80%	-1.20%	15.80%	-5.60%	8.30%	5.80%	—	—	—	—
	31.90%	69.60%	23.30%	8.20%	69.90%	-29.50%	-24.30%	29.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	11,123	11,172	10,933	10,646	12,792	11,287	15,824	13,266	12,258	10,303
	745.65	587.53	328.12	616.06	433.76	670.99	589.86	258.01	109.60	80.65
	11,869	11,759	11,261	11,262	13,226	11,958	16,414	13,524	12,367	10,384
	8,430	8,578	8,903	8,859	11,612	10,246	12,221	11,147	10,403	8,041
	5,187	5,238	5,610	5,761	7,248	5,784	7,216	6,748	6,455	4,893
	58.82	73.20	65.13	203.40	89.23	16.81	26.09	5.51	14.25	3.72
	1,174	1,161	1,063	980.56	1,642	1,600	1,735	1,561	1,363	1,132
	200.22	213.15	230.04	182.60	114.98	16.94	28.68	95.58	130.92	52.89
	284.33	285.36	297.20	254.58	435.35	415.26	487.99	470.48	413.03	354.83
	1,565	1,560	1,705	1,593	2,549	2,367	2,724	2,496	2,306	1,939
	3,439	3,181	2,358	2,403	1,614	1,712	4,193	2,378	1,965	2,343
	-17.38	-17.38	0.00	—	—	-74.71	—	—	—	—
	3,422	3,164	2,358	2,403	1,614	1,637	4,193	2,378	1,965	2,343
	828.68	748.78	611.66	502.82	383.94	182.77	1,080	504.96	434.89	530.17
	2,593	2,415	1,747	1,954	1,230	1,455	3,113	1,873	1,530	1,813
	44.70	41.58	29.97	32.43	21.00	24.83	53.13	31.96	26.11	—
Key metrics
	3,906	3,662	2,886	2,840	2,165	2,070	4,710	2,944	2,509	2,751
	35.12%	32.80%	26.40%	26.70%	16.90%	18.30%	29.80%	22.20%	20.50%	26.70%
	23.31%	21.60%	16.00%	18.40%	9.60%	12.90%	19.70%	14.10%	12.50%	17.60%
	—	14.70%	12.30%	—	—	—	—	—	—	—
	-1.75%	2.20%	2.70%	-16.80%	13.30%	-28.70%	19.30%	8.20%	19.00%	—
	31.16%	38.20%	-10.60%	58.80%	-15.40%	-53.30%	66.20%	22.40%	-15.60%	—
	—	2,412	1,399	—	—	—	—	—	—	—
	—	1.21	0.94	—	—	—	—	—	—	—
	—	0.18	0.23	—	—	—	—	—	—	—
	—	4,022	4,330	—	—	—	—	—	—	—
	—	154.7	159.1	—	—	—	—	—	—	—
Balance sheet
	—	29,279	27,513	—	—	—	—	—	—	—
	—	8,022	7,689	—	—	—	—	—	—	—
	—	160.43	295.26	—	—	—	—	—	—	—
	—	4,210	4,195	—	—	—	—	—	—	—
	—	2,361	2,359	—	—	—	—	—	—	—
	—	554.01	624.99	—	—	—	—	—	—	—
	—	2,420	2,185	—	—	—	—	—	—	—
	—	1,832	1,787	—	—	—	—	—	—	—
	—	6,299	6,420	—	—	—	—	—	—	—
	—	4,182	4,625	—	—	—	—	—	—	—
	—	4,182	4,225	—	—	—	—	—	—	—
	—	0.00	400.00	—	—	—	—	—	—	—
	—	22,718	20,534	—	—	—	—	—	—	—
Cash flow
	—	2,933	1,646	—	—	—	—	—	—	—
	—	-2,025	-2,066	—	—	—	—	—	—	—
	—	-1,072	616.31	—	—	—	—	—	—	—
	—	520.61	246.94	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -4.41%
Sales CAGR 5Y: -6.73%
Profit CAGR 3Y: +25.20%
Profit CAGR 5Y: -4.95%
Sales YoY (TTM): -1.75%
Profit YoY (TTM): +31.16%

Consolidated

Sales CAGR 3Y: +10.63%
Sales CAGR 5Y: +6.32%
Profit CAGR 3Y: +22.03%
Profit CAGR 5Y: -8.07%
Sales YoY (TTM): +9.09%
Profit YoY (TTM): +9.48%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 51.87%

Quarter	September 2026	June 2026
Promoter %	51.87%	51.87%

Holder	Type	Holding	Previous	Change
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING)	Promoter Group	33.54%	33.54%	0.00%
QUANT MUTUAL FUND - QUANT ARBITRAGE FUND	Public	4.91%	—	—
KAMBAM NITHYANANDA REDDY	Promoter	4.37%	4.37%	0.00%
SBI NIFTY MIDCAP 150 INDEX FUND	Public	3.51%	—	—
KIRTHI REDDY KAMBAM	Promoter Group	3.46%	3.46%	0.00%
HDFC MUTUAL FUND-HDFC ARBITRAGE FUND	Public	3.22%	—	—
VENKATA RAMPRASAD REDDY PENAKA	Promoter	3.07%	3.07%	0.00%
AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING)	Promoter Group	2.86%	2.86%	0.00%
LIFE INSURANCE CORPORATION OF INDIA	Public	2.85%	2.94%	-0.09%
NPS TRUST A/C - SBI PENSION FUND - UPS - CG SCHEM	Public	2.80%	—	—
MEENAKSHISUNDERAM SIVAKUMARAN	Promoter Group	2.48%	—	—
KAMBAM SPOORTHI	Promoter Group	1.20%	1.20%	0.00%
KOTTAMANCHI RAJESWARI	Promoter Group	0.31%	0.31%	0.00%
M SUMANTH KUMAR REDDY	Promoter Group	0.27%	0.27%	0.00%
TRIDENT CHEMPHAR LIMITED	Promoter Group	0.13%	0.13%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Submission of Financial results for the Quarter and Half year ended September 30, 2026.4 Nov 2026 · Result / Financial Results
Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027.4 Nov 2026 · Company Update / Change in Directorate
Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company.4 Nov 2026 · Company Update / Acquisition
Approved the proposal of Merger of two wholly owned subsidiaries of the Company.4 Nov 2026 · Company Update / Restructuring
Intimation of record date for payment of interim dividend for FY 2026-2027.4 Nov 2026 · Corp. Action / Record Date
Intimation of declaration of interim dividend for FY 2026-27.4 Nov 2026 · Corp. Action / Dividend
Submission of Earnings Presentation on Q2 FY27 Financial Results.4 Nov 2026 · Company Update / Investor Presentation
Submission of Press Release on Q2 FY27 financial results4 Nov 2026 · Company Update / Press Release / Media Release
Submission of outcome of Board Meeting held on November 4, 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Earnings Call scheduled to be held on November 5, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026.26 Oct 2026 · Company Update / Analyst / Investor Meet
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....26 Oct 2026 · Board Meeting / Board Meeting
Submission of Notice published in newspapers.9 Oct 2026 · Company Update / Newspaper Publication
Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.5 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.3 Oct 2026 · Company Update / Press Release / Media Release
Intimation of completion of acquisition.2 Oct 2026 · Company Update / General
Intimation of acquisition of a step down subsidiary in USA.2 Oct 2026 · Company Update / Acquisition
Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted, a step down subsidiary of the Company.1 Oct 2026 · Company Update / Acquisition
Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.30 Sep 2026 · Company Update / Press Release / Media Release
Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana.29 Sep 2026 · Company Update / General
Intimation of closure of trading window.24 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of investor Analyst meet scheduled on 24.09.2026.21 Sep 2026 · Company Update / Analyst / Investor Meet
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.15 Sep 2026 · Company Update / General
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.15 Sep 2026 · Company Update / Press Release / Media Release
Intimation of subscription of 10,000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company.12 Sep 2026 · Company Update / Acquisition
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.11 Sep 2026 · Company Update / General
Intimation of investor / analyst meet scheduled on 22.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of investor / analyst meet scheduled on 21.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of investor / analyst meet scheduled on 17.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of investor / analyst meet scheduled on 18.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of Investor / analyst meet scheduled on 17.09.2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Submission of notice published in newspapers.3 Sep 2026 · Company Update / Newspaper Publication
Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited'' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.1 Sep 2026 · Company Update / Acquisition
Submission of Press Release.31 Aug 2026 · Company Update / Press Release / Media Release (Revised)
Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.28 Aug 2026 · Company Update / General
Submission of Voting Results and Scrutinizer''s Report of 39th AGM of the Company held on August 27, 2026.28 Aug 2026 · AGM/EGM / AGM
Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August, 2026.27 Aug 2026 · AGM/EGM / AGM
Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong25 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Investor/ Analyst meet scheduled on September 1, 2026.25 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.24 Aug 2026 · Company Update / General
Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.21 Aug 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Buy Back of Shares	17 Apr 2026	17 Apr 2026	—
Interim Dividend - Rs. - 4.0000	8 Aug 2025	8 Aug 2025	—
Buy Back of Shares	30 Jul 2024	30 Jul 2024	—

Board meetings

4 Nov 2026 Board Meeting - Financial Results
5 Aug 2026 Board Meeting - Financial Results